Watch for stockholder vote on preferred share conversion; key near-term catalysts include KP-104 Phase 2 renal data in Q4 2026 and briquilimab pre-BLA meeting in Q1 2027. The massive dilution may pressure the stock near-term, but the cash runway reduces financing risk.
Price Chart
Executive Summary
Jasper Therapeutics acquired Kira Pharmaceuticals in an all-stock transaction, concurrent with a $132M private placement. Existing Jasper shareholders will own only ~6.68% of the combined company, representing massive dilution but providing cash runway through H2 2028 to advance a pipeline including KP-104 (PNH/renal) and briquilimab (SCID).
Key Facts
- All-stock acquisition of Kira Pharmaceuticals; existing Jasper shareholders retain ~6.68% ownership on a fully diluted basis
- Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital
- Pro-forma cash expected to fund operations through H2 2028, covering multiple clinical milestones
- Combined company pipeline: KP-104 (Phase 2/3-ready complement inhibitor), briquilimab (late-stage anti-KIT), KP-701 (preclinical)
- Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus milestones
- Approximately 653.6 million shares outstanding post-transaction on an as-converted basis
Financial Impact
$132M private placement + $12M upfront out-licensing + $30M CVR potential; massive dilution from ~19M market cap to ~653.6M shares
Risk Factors
- Dilution risk: existing shareholders own ~6.68% of combined company
- Stockholder approval required for preferred conversion
- Pipeline execution risk: KP-104 and briquilimab still in clinical stages
- No revenue; dependence on continued financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328849 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5054 (−0.90%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5054 (+1.10%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5054 (−5.02%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5054 (+5.00%) |
Oct 14, 2026 11d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5054 (+5.02%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5054 (+17.03%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5054 (−36.03%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5054 (−19.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers